MDX Meldex

Medisico plc - Admission Announcement

London, August 19                                               19 August 2014

                                 Medisico plc

                         ("Medisico" or "the Company")

                            Admission Announcement

The Directors of Medisico plc are pleased to announce that the Company's shares
will commence trading on 19 August 2014 on GXG First Quote Market under the
symbol MDX.

Medisico plc is a life sciences company delivering medical and aesthetic
treatments. These are developed from proprietary IP and technologies. The
therapies and treatments are delivered via highly trained clinical partners.

Medisico has evolved into a group with four subsidiaries, Medisico Aesthetic
Medicine Ltd, an aesthetic medical division, Medisico Clinics Ltd, a clinical
division will operate aesthetic treatments, minor surgery and primary care
treatments, Medisico Academy Ltd, which will concentrate on education and
training as well as delivering the R&D from their IP, and Medisico General
Medicine Ltd, a general medical division which will undertake a programme of
clinical trials. (The first of these studies will be on ulcer and ulcer cure,
and vaginal laxity treatment.) Each of these subsidiaries has a separate
management team reporting to the Medisico board, thus allowing each to focus on
specific market segments.

Medisico plans to launch wholly-owned dentistry and e-procurement subsidiaries
in late 2014 or early 2015 as well majority-owned subsidiaries in Europe, South
Africa, Australasia and the Middle East in conjunction with equally driven and
socially responsible partners in those regions.

The directors of Medisico accept responsibility for this announcement.

Disclaimer

This Document includes "forward-looking statements." All statements other than
statements of historical fact within this Document, including statements
regarding Medisico plc, plans, objectives and expectations, are all
forward-looking statements. Although Medisico plc believes that the
expectations reflected in such forward-looking statements are reasonable at
this time, it can give no assurance that such expectations will prove to have
been correct. There will always be factors beyond the Company's control that
may cause actual results to differ materially from expectations. As such
subsequent written and oral forward-looking statements attributable to Medisico
plc or persons acting on its behalf are expressly qualified in this regard.